title: Identification of a 20-gene expression-based risk score as a predictor of clinical outcome in chronic lymphocytic leukemia patients.
abstract: Despite the improvement in treatment options, chronic lymphocytic leukemia (CLL) remains an incurable disease and patients show a heterogeneous clinical course requiring therapy for many of them. In the current work, we have built a 20-gene expression (GE)-based risk score predictive for patients overall survival and improving risk classification using microarray gene expression data. GE-based risk score allowed identifying a high-risk group associated with a significant shorter overall survival (OS) and time to treatment (TTT) (P ≤ .01), comprising 19.6% and 13.6% of the patients in two independent cohorts. GE-based risk score, and NRIP1 and TCF7 gene expression remained independent prognostic factors using multivariate Cox analyses and combination of GE-based risk score together with NRIP1 and TCF7 gene expression enabled the identification of three clinically distinct groups of CLL patients. Therefore, this GE-based risk score represents a powerful tool for risk stratification and outcome prediction of CLL patients and could thus be used to guide clinical and therapeutic decisions prospectively.
authors.affiliation: INSERM, U1040, F-34197, Institute of Research in Biotherapy, CHU Montpellier, 80 Avenue Augustin Fliche, 34285 Montpellier Cedex, France.
authors.forename: Elias
authors.initials: E
authors.lastname: Bou Samra
authors.affiliation: INSERM, U1040, F-34197, Institute of Research in Biotherapy, CHU Montpellier, 80 Avenue Augustin Fliche, 34285 Montpellier Cedex, France ; CHU Montpellier, Institute of Research in Biotherapy, Montpellier, 80 Avenue Augustin Fliche, 34285 Montpellier, France ; Université Montpellier 1, UFR Médecine, Montpellier, 80 Avenue Augustin Fliche, 34285 Montpellier, France.
authors.forename: Bernard
authors.initials: B
authors.lastname: Klein
authors.affiliation: INSERM, U1040, F-34197, Institute of Research in Biotherapy, CHU Montpellier, 80 Avenue Augustin Fliche, 34285 Montpellier Cedex, France ; Institut de Biologie Computationnelle, Université Montpellier 2, 2 Place Eugène Bataillon, 34095 Montpellier Cedex 5, France.
authors.forename: Thérèse
authors.initials: T
authors.lastname: Commes
authors.affiliation: INSERM, U1040, F-34197, Institute of Research in Biotherapy, CHU Montpellier, 80 Avenue Augustin Fliche, 34285 Montpellier Cedex, France ; CHU Montpellier, Institute of Research in Biotherapy, Montpellier, 80 Avenue Augustin Fliche, 34285 Montpellier, France ; Université Montpellier 1, UFR Médecine, Montpellier, 80 Avenue Augustin Fliche, 34285 Montpellier, France.
authors.forename: Jérôme
authors.initials: J
authors.lastname: Moreaux
mesh_terms: D048868:Adaptor Proteins, Signal Transducing / Q000096:biosynthesis; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000235:genetics* / Q000473:pathology; D046228:Microarray Analysis; D009363:Neoplasm Proteins / Q000096:biosynthesis*; D009687:Nuclear Proteins / Q000096:biosynthesis; D000078723:Nuclear Receptor Interacting Protein 1; D011379:Prognosis; D016019:Survival Analysis; D051822:T Cell Transcription Factor 1 / Q000096:biosynthesis; D016896:Treatment Outcome
chemical_list: D048868:Adaptor Proteins, Signal Transducing; D009363:Neoplasm Proteins; D009687:Nuclear Proteins; D000078723:Nuclear Receptor Interacting Protein 1; D051822:T Cell Transcription Factor 1; C497576:TCF7 protein, human